CANF — Can-Fite BioPharma Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1536196 ·
Last close
$3.44
Market Cap
$7.37M
52W High
$10.40
52W Low
$2.83
ADV30
994,474
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 9,514,000 | 5,528,000 | 3,922,000 |
| Jun 2025 | — | — | — | — | — | — | 3,536,000 |
| Dec 2024 | — | — | — | — | 9,120,000 | 4,825,000 | 3,684,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-176,189,000
Inventory
—
Receivables
—
ST Investments
$3,012,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$405,000
EBITDA
$-9,926,000
Free Cash Flow
$-4,985,750
Enterprise Value
$6,100,316
Total Cash
$8,540,000
Total Debt
$71,000
Shares Out
2,142,547
Trailing EPS
$-10.75
Book Value
$4.27
ROE
-178.2%
ROA
-66.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 405,000 | -9,950,000 | -9,828,000 | 9,514,000 | 3,922,000 | — | -8,949,000 |
| Dec 2024 | 674,000 | -8,130,000 | -7,880,000 | 9,120,000 | 3,684,000 | — | -7,637,000 |
| Dec 2023 | 743,000 | -8,195,000 | -7,634,000 | 9,989,000 | 3,746,000 | — | -8,440,000 |
| Dec 2022 | 810,000 | -10,096,000 | -10,173,000 | 9,283,000 | 4,811,000 | — | -10,801,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SXTC | China SXT Pharmaceuticals, Inc. | $7.44M | $1.67 | — |
| SNGX | SOLIGENIX, INC. | $7.60M | $0.51 | — |
| CNSP | CNS Pharmaceuticals, Inc. | $7.63M | $5.22 | — |
| BETRF | BetterLife Pharma Inc. | $7.67M | $0.05 | — |
| XBIO | Xenetic Biosciences, Inc. | $7.02M | $3.07 | — |
News headlines (Yahoo Finance, 1h cache)
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
2026-05-18 11:00 · Yahoo
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
2026-05-13 11:00 · Yahoo
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
2026-04-30 12:31 · Yahoo
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
2026-03-30 11:20 · Yahoo
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
2026-03-26 13:27 · Yahoo
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
2026-03-17 11:47 · Yahoo
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
2026-03-05 14:18 · Yahoo
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
2026-03-04 15:25 · Yahoo
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
2026-03-04 12:00 · Yahoo
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
2026-02-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.